Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Study Objective: To gather additional 28-day all-cause mortality and safety data among adult patients with severe sepsis who were treated with drotrecogin alfa (activated).

Design: Prospective, single-arm, multicenter clinical trial.

Setting: Eighty-five study sites in the United States and two in Puerto Rico.

Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report.

Hypocomplementemic urticarial vasculitis (HUV) is often misdiagnosed. The response to drug therapy may be unsatisfactory, and immunosuppressive therapy may be associated with significant side effects. A 35-year-old patient whose condition was resistant to cyclophosphamide, corticosteroids, pentoxyphylline, cyproheptadine, sulindac, and colchicine was maintained in remission with dapsone, which may be the drug of choice for HUV.

Sarcoidosis involving the thyroid and pleura.

We report the coincidence of uncommon manifestations of sarcoidosis, each confirmed by percutaneous needle biopsy, revealing noncaseating granulomas. A patients presented with a thyroid nodule which demonstrated noncaseating granulomas on biopsy. When pleural effusion subsequently developed, pleural biopsy demonstrated noncaseating granulomas with no acid fast bacilli on stain or culture, and a diagnosis of sarcoidosis was made.

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

Objective: To test the effect of a novel bradykinin antagonist, deltibant (CP-0127), on survival, organ dysfunction, and other outcomes in patients with the systemic inflammatory response syndrome (SIRS) and presumed sepsis.

Design: Multicenter, randomized, placebo-controlled, double-blind, parallel, dose-ranging trial. Follow-up for 28 days or until death.